Contacts
Nathan Harrill
Exact Sciences Corp.
investorrelations@exactsciences.com
608-535-8659
Exact Sciences Corp. (Nasdaq:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Fourth quarter 2023 webcast & conference call details
Date: |
Wednesday, February 21, 2024 |
Time: |
5 p.m. ET |
Webcast: |
The live webcast can be accessed at www.exactsciences.com |
Telephone: |
Domestic callers, dial 888-330-2384 |
International callers, dial +1 240-789-2701 |
|
|
Access code for both domestic and international callers: 4437608 |
A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201496564/en/
Related news for (EXAS)
- Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
- Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
- Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium
- Exact Sciences Announces Preliminary Fourth Quarter 2024 Results
- Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy